{
  "symbol": "CRNX",
  "company_name": "Crinetics Pharmaceuticals Inc",
  "ir_website": "https://ir.crinetics.com/",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Press Release Example 1",
          "url": "https://ir.crinetics.com/press-release-example-1",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![Crinetics Pharmaceuticals CRNX San Diego Logo](/sites/g/files/knoqqb69441/themes/site/nir_pid2888/client/images/Crinetics_Logo_onWhite.png) ](https://www.crinetics.com/)\n\n  * [Pipeline](https://crinetics.com/pipeline/)\n    * [Research Pipeline](https://crinetics.com/pipeline/)\n    * [Paltusotine](https://crinetics.com/pipeline/paltusotine-oral-sst2-selective-agonist-acromegaly-neuroendocrine-tumors-nets/)\n    * [CRN04894, Oral ACTH Antagonist](https://crinetics.com/pipeline/crn04894-cushings-disease-cah/)\n    * [Oral PTH Antagonist](https://crinetics.com/oral-pth-antagonist-treatment-of-hypercalcemia/)\n  * [Patients](https://crinetics.com/patients/)\n    * [Clinical Trials](https://crinetics.com/what-are-clinical-trials-why-are-they-important/)\n    * [Expanded Access Policy](https://crinetics.com/expanded-access-policy/)\n    * [Letter to Acromegaly Community](https://crinetics.com/acromegaly-community-pathfndr1-letter/)\n    * [Patient Videos >](https://crinetics.com/)\n      * [Clinical Trials](https://crinetics.com/patient-video-acromegaly-clinical-trials/)\n      * [Acromegaly in a Pandemic](https://crinetics.com/acromegaly-covid19-pandemic/)\n      * [Acromegaly Symptoms](https://crinetics.com/patient-video-acromegaly-symptoms/)\n      * [Acromegaly Diagnosis](https://crinetics.com/patient-video-acromegaly-diagnosis/)\n      * [Acromegaly Advocate](https://crinetics.com/patient-video-acromegaly-be-your-own-advocate/)\n      * [Acromegaly Support](https://crinetics.com/patient-video-acromegaly-finding-support/)\n  * [Professionals](https://crinetics.com/professionals/)\n    * [Acromegaly](https://crinetics.com/acromegaly-symptoms-diagnosis-treatment-resources/)\n    * [Carcinoid Syndrome](https://crinetics.com/carcinoid-syndrome-symptoms-diagnosis-treatment/)\n  * [Investors](/)\n    * [Overview](https://ir.crinetics.com/)\n    * [Corporate Presentation](/investor-resources/corporate-presentation)\n    * [SEC Filings](/investor-resources/sec-filings)\n    * [Stock Information](/investor-resources/stock-information)\n    * [Corporate Governance](/investor-resources/corporate-governance)\n    * [Press Releases](https://crinetics.com/press-releases/)\n    * [Events & Presentations](https://crinetics.com/events/)\n    * [Analyst Coverage](/investor-resources/analyst-coverage)\n    * [Investor Resources](/investor-resources)\n    * [Unmet Medical Need in Acromegaly](https://crinetics.com/access-current-treatment-landscape-and-unmet-medical-need-in-acromegaly-webinar/)\n  * [About Us](https://crinetics.com/about-crinetics-pharmaceuticals-crnx/)\n    * [Meet Us](https://crinetics.com/about-us/)\n    * [Employee Spotlight](https://crinetics.com/careers/culture/employee-spotlight/)\n    * [Culture](https://crinetics.com/careers/culture/)\n    * [Community](https://www.crinetics.com/about/community/)\n  * [Careers](https://crinetics.com/careers/)\n    * [Culture >](https://crinetics.com/careers/culture/)\n    * [Job Listings](https://crinetics.com/careers/job-listings/)\n    * [Benefits](https://crinetics.com/careers/benefits/)\n  * [Contact](https://crinetics.com/contact/)\n    * [Contact Us](https://crinetics.com/contact/)\n    * [Partnering](https://crinetics.com/partnering/)\n    * [Grants and Funding](https://crinetics.com/contact/grants-and-funding/)\n\n\n\n<https://www.crinetics.com/wp-content/uploads/2020/07/808-Rotation-D3.mp4>\n\n#  Page Not Found \n\n### [Events ![Events link](/system/files-encrypted/nasdaq_kms/inline-images/Crin_Home_Boxes_Grey-432x240-Events.jpg) ](https://crinetics.com/events/)\n\n### [Press Releases ![Press Releases link](/system/files-encrypted/nasdaq_kms/inline-images/Crin_Home_Box_PressRelease_Grey-uai-720x400.jpg) ](https://crinetics.com/press-releases/)\n\n### [Investor Home ![Investor Home](/system/files-encrypted/nasdaq_kms/inline-images/Crin_Home_Box_Financials_Grey-uai-720x400.jpg) ](/)\n\n##  Investor Resources\n\n  * [Corporate Presentation>](/investor-resources/corporate-presentation)\n  * [Stock Information>](/investor-resources/stock-information)\n  * [SEC Filings>](/investor-resources/sec-filings)\n  * [Analyst Coverage>](/investor-resources/analyst-coverage)\n  * [Investor FAQ>](/investor-resources/investor-faq)\n  * [Corporate Governance>](/investor-resources/corporate-governance)\n  * [Committee>](/investor-resources/committee-composition)\n  * [IR Home>](/)\n\n\n\n# Page Not Found\n\nWe are sorry, the page you requested cannot be found. Please check the URL or visit our [Homepage](/).\n\n  * ### [Email Alerts ](/#email-alerts \"Email Alerts\")\n  * ### [RSS Feeds ](/investor-resources/rss-feeds \"RSS Feeds\")\n  * ### [Print ](javascript:window.print\\(\\); \"Print\")\n  * ### [Email Page ](# \"Email Page\")\n\n\n\n### [Events ![Events link](/system/files-encrypted/nasdaq_kms/inline-images/Crin_Home_Boxes_Grey-432x240-Events.jpg) ](https://crinetics.com/events/)\n\n### [Press Releases ![Press Releases link](/system/files-encrypted/nasdaq_kms/inline-images/Crin_Home_Box_PressRelease_Grey-uai-720x400.jpg) ](https://crinetics.com/press-releases/)\n\n### [Investor Home ![Investor Home](/system/files-encrypted/nasdaq_kms/inline-images/Crin_Home_Box_Financials_Grey-uai-720x400.jpg) ](/)\n\n## Contact\n\n  * [Press Releases & Events>](#email-alerts-two)\n  * [Financial Alerts>](#email-alerts-one)\n  * [Media Inquiries>](#media-inquiries)\n  * [Contact IR>](#contact-ir)\n\n\n\nRequired fields denoted by an asterisk ().\n\nHide lower priority columns\n\nAlert type  \n---  \nQuote  \nSEC Filing  \nWeekly Summary  \n  \nEmail\n\n*By clicking Submit, you agree to our [privacy policy](https://crinetics.com/privacy-policy.)\n\nLeave this field blank\n\nFirst Name\n\nLast Name\n\nemail@address.com\n\nOrganization\n\nMessage\n\nLeave this field blank\n\n##  Contact\n\n[ Press Releases & Events> ](#1600129535-2-99)\n\n[ Financial Alerts> ](#1600129535-2-42)\n\nRequired fields denoted by an asterisk ().\n\nHide lower priority columns\n\nAlert type  \n---  \nQuote  \nSEC Filing  \nWeekly Summary  \n  \nEmail\n\n*By clicking Submit, you agree to our [privacy policy](https://crinetics.com/privacy-policy.)\n\nLeave this field blank\n\n[ Media Inquiries> ](#1600129613243-24-8)\n\n[ Contact IR> ](#1600129613243-2-8)\n\nFirst Name\n\nLast Name\n\nemail@address.com\n\nOrganization\n\nMessage\n\nLeave this field blank\n\n[](#)\n\n### Privacy Preference Center\n\n#### Privacy Preferences\n"
        },
        {
          "title": "Press Release Example 2",
          "url": "https://ir.crinetics.com/press-release-example-2",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![Crinetics Pharmaceuticals CRNX San Diego Logo](/sites/g/files/knoqqb69441/themes/site/nir_pid2888/client/images/Crinetics_Logo_onWhite.png) ](https://www.crinetics.com/)\n\n  * [Pipeline](https://crinetics.com/pipeline/)\n    * [Research Pipeline](https://crinetics.com/pipeline/)\n    * [Paltusotine](https://crinetics.com/pipeline/paltusotine-oral-sst2-selective-agonist-acromegaly-neuroendocrine-tumors-nets/)\n    * [CRN04894, Oral ACTH Antagonist](https://crinetics.com/pipeline/crn04894-cushings-disease-cah/)\n    * [Oral PTH Antagonist](https://crinetics.com/oral-pth-antagonist-treatment-of-hypercalcemia/)\n  * [Patients](https://crinetics.com/patients/)\n    * [Clinical Trials](https://crinetics.com/what-are-clinical-trials-why-are-they-important/)\n    * [Expanded Access Policy](https://crinetics.com/expanded-access-policy/)\n    * [Letter to Acromegaly Community](https://crinetics.com/acromegaly-community-pathfndr1-letter/)\n    * [Patient Videos >](https://crinetics.com/)\n      * [Clinical Trials](https://crinetics.com/patient-video-acromegaly-clinical-trials/)\n      * [Acromegaly in a Pandemic](https://crinetics.com/acromegaly-covid19-pandemic/)\n      * [Acromegaly Symptoms](https://crinetics.com/patient-video-acromegaly-symptoms/)\n      * [Acromegaly Diagnosis](https://crinetics.com/patient-video-acromegaly-diagnosis/)\n      * [Acromegaly Advocate](https://crinetics.com/patient-video-acromegaly-be-your-own-advocate/)\n      * [Acromegaly Support](https://crinetics.com/patient-video-acromegaly-finding-support/)\n  * [Professionals](https://crinetics.com/professionals/)\n    * [Acromegaly](https://crinetics.com/acromegaly-symptoms-diagnosis-treatment-resources/)\n    * [Carcinoid Syndrome](https://crinetics.com/carcinoid-syndrome-symptoms-diagnosis-treatment/)\n  * [Investors](/)\n    * [Overview](https://ir.crinetics.com/)\n    * [Corporate Presentation](/investor-resources/corporate-presentation)\n    * [SEC Filings](/investor-resources/sec-filings)\n    * [Stock Information](/investor-resources/stock-information)\n    * [Corporate Governance](/investor-resources/corporate-governance)\n    * [Press Releases](https://crinetics.com/press-releases/)\n    * [Events & Presentations](https://crinetics.com/events/)\n    * [Analyst Coverage](/investor-resources/analyst-coverage)\n    * [Investor Resources](/investor-resources)\n    * [Unmet Medical Need in Acromegaly](https://crinetics.com/access-current-treatment-landscape-and-unmet-medical-need-in-acromegaly-webinar/)\n  * [About Us](https://crinetics.com/about-crinetics-pharmaceuticals-crnx/)\n    * [Meet Us](https://crinetics.com/about-us/)\n    * [Employee Spotlight](https://crinetics.com/careers/culture/employee-spotlight/)\n    * [Culture](https://crinetics.com/careers/culture/)\n    * [Community](https://www.crinetics.com/about/community/)\n  * [Careers](https://crinetics.com/careers/)\n    * [Culture >](https://crinetics.com/careers/culture/)\n    * [Job Listings](https://crinetics.com/careers/job-listings/)\n    * [Benefits](https://crinetics.com/careers/benefits/)\n  * [Contact](https://crinetics.com/contact/)\n    * [Contact Us](https://crinetics.com/contact/)\n    * [Partnering](https://crinetics.com/partnering/)\n    * [Grants and Funding](https://crinetics.com/contact/grants-and-funding/)\n\n\n\n<https://www.crinetics.com/wp-content/uploads/2020/07/808-Rotation-D3.mp4>\n\n#  Page Not Found \n\n### [Events ![Events link](/system/files-encrypted/nasdaq_kms/inline-images/Crin_Home_Boxes_Grey-432x240-Events.jpg) ](https://crinetics.com/events/)\n\n### [Press Releases ![Press Releases link](/system/files-encrypted/nasdaq_kms/inline-images/Crin_Home_Box_PressRelease_Grey-uai-720x400.jpg) ](https://crinetics.com/press-releases/)\n\n### [Investor Home ![Investor Home](/system/files-encrypted/nasdaq_kms/inline-images/Crin_Home_Box_Financials_Grey-uai-720x400.jpg) ](/)\n\n##  Investor Resources\n\n  * [Corporate Presentation>](/investor-resources/corporate-presentation)\n  * [Stock Information>](/investor-resources/stock-information)\n  * [SEC Filings>](/investor-resources/sec-filings)\n  * [Analyst Coverage>](/investor-resources/analyst-coverage)\n  * [Investor FAQ>](/investor-resources/investor-faq)\n  * [Corporate Governance>](/investor-resources/corporate-governance)\n  * [Committee>](/investor-resources/committee-composition)\n  * [IR Home>](/)\n\n\n\n# Page Not Found\n\nWe are sorry, the page you requested cannot be found. Please check the URL or visit our [Homepage](/).\n\n  * ### [Email Alerts ](/#email-alerts \"Email Alerts\")\n  * ### [RSS Feeds ](/investor-resources/rss-feeds \"RSS Feeds\")\n  * ### [Print ](javascript:window.print\\(\\); \"Print\")\n  * ### [Email Page ](# \"Email Page\")\n\n\n\n### [Events ![Events link](/system/files-encrypted/nasdaq_kms/inline-images/Crin_Home_Boxes_Grey-432x240-Events.jpg) ](https://crinetics.com/events/)\n\n### [Press Releases ![Press Releases link](/system/files-encrypted/nasdaq_kms/inline-images/Crin_Home_Box_PressRelease_Grey-uai-720x400.jpg) ](https://crinetics.com/press-releases/)\n\n### [Investor Home ![Investor Home](/system/files-encrypted/nasdaq_kms/inline-images/Crin_Home_Box_Financials_Grey-uai-720x400.jpg) ](/)\n\n## Contact\n\n  * [Press Releases & Events>](#email-alerts-two)\n  * [Financial Alerts>](#email-alerts-one)\n  * [Media Inquiries>](#media-inquiries)\n  * [Contact IR>](#contact-ir)\n\n\n\nRequired fields denoted by an asterisk ().\n\nHide lower priority columns\n\nAlert type  \n---  \nQuote  \nSEC Filing  \nWeekly Summary  \n  \nEmail\n\n*By clicking Submit, you agree to our [privacy policy](https://crinetics.com/privacy-policy.)\n\nLeave this field blank\n\nFirst Name\n\nLast Name\n\nemail@address.com\n\nOrganization\n\nMessage\n\nLeave this field blank\n\n##  Contact\n\n[ Press Releases & Events> ](#1600129535-2-99)\n\n[ Financial Alerts> ](#1600129535-2-42)\n\nRequired fields denoted by an asterisk ().\n\nHide lower priority columns\n\nAlert type  \n---  \nQuote  \nSEC Filing  \nWeekly Summary  \n  \nEmail\n\n*By clicking Submit, you agree to our [privacy policy](https://crinetics.com/privacy-policy.)\n\nLeave this field blank\n\n[ Media Inquiries> ](#1600129613243-24-8)\n\n[ Contact IR> ](#1600129613243-2-8)\n\nFirst Name\n\nLast Name\n\nemail@address.com\n\nOrganization\n\nMessage\n\nLeave this field blank\n\n[](#)\n\n### Privacy Preference Center\n\n#### Privacy Preferences\n"
        }
      ]
    },
    {
      "section_name": "Financial Reports",
      "links": [
        {
          "title": "Annual Report 2024",
          "url": "https://ir.crinetics.com/annual-report-2024",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![Crinetics Pharmaceuticals CRNX San Diego Logo](/sites/g/files/knoqqb69441/themes/site/nir_pid2888/client/images/Crinetics_Logo_onWhite.png) ](https://www.crinetics.com/)\n\n  * [Pipeline](https://crinetics.com/pipeline/)\n    * [Research Pipeline](https://crinetics.com/pipeline/)\n    * [Paltusotine](https://crinetics.com/pipeline/paltusotine-oral-sst2-selective-agonist-acromegaly-neuroendocrine-tumors-nets/)\n    * [CRN04894, Oral ACTH Antagonist](https://crinetics.com/pipeline/crn04894-cushings-disease-cah/)\n    * [Oral PTH Antagonist](https://crinetics.com/oral-pth-antagonist-treatment-of-hypercalcemia/)\n  * [Patients](https://crinetics.com/patients/)\n    * [Clinical Trials](https://crinetics.com/what-are-clinical-trials-why-are-they-important/)\n    * [Expanded Access Policy](https://crinetics.com/expanded-access-policy/)\n    * [Letter to Acromegaly Community](https://crinetics.com/acromegaly-community-pathfndr1-letter/)\n    * [Patient Videos >](https://crinetics.com/)\n      * [Clinical Trials](https://crinetics.com/patient-video-acromegaly-clinical-trials/)\n      * [Acromegaly in a Pandemic](https://crinetics.com/acromegaly-covid19-pandemic/)\n      * [Acromegaly Symptoms](https://crinetics.com/patient-video-acromegaly-symptoms/)\n      * [Acromegaly Diagnosis](https://crinetics.com/patient-video-acromegaly-diagnosis/)\n      * [Acromegaly Advocate](https://crinetics.com/patient-video-acromegaly-be-your-own-advocate/)\n      * [Acromegaly Support](https://crinetics.com/patient-video-acromegaly-finding-support/)\n  * [Professionals](https://crinetics.com/professionals/)\n    * [Acromegaly](https://crinetics.com/acromegaly-symptoms-diagnosis-treatment-resources/)\n    * [Carcinoid Syndrome](https://crinetics.com/carcinoid-syndrome-symptoms-diagnosis-treatment/)\n  * [Investors](/)\n    * [Overview](https://ir.crinetics.com/)\n    * [Corporate Presentation](/investor-resources/corporate-presentation)\n    * [SEC Filings](/investor-resources/sec-filings)\n    * [Stock Information](/investor-resources/stock-information)\n    * [Corporate Governance](/investor-resources/corporate-governance)\n    * [Press Releases](https://crinetics.com/press-releases/)\n    * [Events & Presentations](https://crinetics.com/events/)\n    * [Analyst Coverage](/investor-resources/analyst-coverage)\n    * [Investor Resources](/investor-resources)\n    * [Unmet Medical Need in Acromegaly](https://crinetics.com/access-current-treatment-landscape-and-unmet-medical-need-in-acromegaly-webinar/)\n  * [About Us](https://crinetics.com/about-crinetics-pharmaceuticals-crnx/)\n    * [Meet Us](https://crinetics.com/about-us/)\n    * [Employee Spotlight](https://crinetics.com/careers/culture/employee-spotlight/)\n    * [Culture](https://crinetics.com/careers/culture/)\n    * [Community](https://www.crinetics.com/about/community/)\n  * [Careers](https://crinetics.com/careers/)\n    * [Culture >](https://crinetics.com/careers/culture/)\n    * [Job Listings](https://crinetics.com/careers/job-listings/)\n    * [Benefits](https://crinetics.com/careers/benefits/)\n  * [Contact](https://crinetics.com/contact/)\n    * [Contact Us](https://crinetics.com/contact/)\n    * [Partnering](https://crinetics.com/partnering/)\n    * [Grants and Funding](https://crinetics.com/contact/grants-and-funding/)\n\n\n\n<https://www.crinetics.com/wp-content/uploads/2020/07/808-Rotation-D3.mp4>\n\n#  Page Not Found \n\n### [Events ![Events link](/system/files-encrypted/nasdaq_kms/inline-images/Crin_Home_Boxes_Grey-432x240-Events.jpg) ](https://crinetics.com/events/)\n\n### [Press Releases ![Press Releases link](/system/files-encrypted/nasdaq_kms/inline-images/Crin_Home_Box_PressRelease_Grey-uai-720x400.jpg) ](https://crinetics.com/press-releases/)\n\n### [Investor Home ![Investor Home](/system/files-encrypted/nasdaq_kms/inline-images/Crin_Home_Box_Financials_Grey-uai-720x400.jpg) ](/)\n\n##  Investor Resources\n\n  * [Corporate Presentation>](/investor-resources/corporate-presentation)\n  * [Stock Information>](/investor-resources/stock-information)\n  * [SEC Filings>](/investor-resources/sec-filings)\n  * [Analyst Coverage>](/investor-resources/analyst-coverage)\n  * [Investor FAQ>](/investor-resources/investor-faq)\n  * [Corporate Governance>](/investor-resources/corporate-governance)\n  * [Committee>](/investor-resources/committee-composition)\n  * [IR Home>](/)\n\n\n\n# Page Not Found\n\nWe are sorry, the page you requested cannot be found. Please check the URL or visit our [Homepage](/).\n\n  * ### [Email Alerts ](/#email-alerts \"Email Alerts\")\n  * ### [RSS Feeds ](/investor-resources/rss-feeds \"RSS Feeds\")\n  * ### [Print ](javascript:window.print\\(\\); \"Print\")\n  * ### [Email Page ](# \"Email Page\")\n\n\n\n### [Events ![Events link](/system/files-encrypted/nasdaq_kms/inline-images/Crin_Home_Boxes_Grey-432x240-Events.jpg) ](https://crinetics.com/events/)\n\n### [Press Releases ![Press Releases link](/system/files-encrypted/nasdaq_kms/inline-images/Crin_Home_Box_PressRelease_Grey-uai-720x400.jpg) ](https://crinetics.com/press-releases/)\n\n### [Investor Home ![Investor Home](/system/files-encrypted/nasdaq_kms/inline-images/Crin_Home_Box_Financials_Grey-uai-720x400.jpg) ](/)\n\n## Contact\n\n  * [Press Releases & Events>](#email-alerts-two)\n  * [Financial Alerts>](#email-alerts-one)\n  * [Media Inquiries>](#media-inquiries)\n  * [Contact IR>](#contact-ir)\n\n\n\nRequired fields denoted by an asterisk ().\n\nHide lower priority columns\n\nAlert type  \n---  \nQuote  \nSEC Filing  \nWeekly Summary  \n  \nEmail\n\n*By clicking Submit, you agree to our [privacy policy](https://crinetics.com/privacy-policy.)\n\nLeave this field blank\n\nFirst Name\n\nLast Name\n\nemail@address.com\n\nOrganization\n\nMessage\n\nLeave this field blank\n\n##  Contact\n\n[ Press Releases & Events> ](#1600129535-2-99)\n\n[ Financial Alerts> ](#1600129535-2-42)\n\nRequired fields denoted by an asterisk ().\n\nHide lower priority columns\n\nAlert type  \n---  \nQuote  \nSEC Filing  \nWeekly Summary  \n  \nEmail\n\n*By clicking Submit, you agree to our [privacy policy](https://crinetics.com/privacy-policy.)\n\nLeave this field blank\n\n[ Media Inquiries> ](#1600129613243-24-8)\n\n[ Contact IR> ](#1600129613243-2-8)\n\nFirst Name\n\nLast Name\n\nemail@address.com\n\nOrganization\n\nMessage\n\nLeave this field blank\n\n[](#)\n\n### Privacy Preference Center\n\n#### Privacy Preferences\n"
        },
        {
          "title": "Quarterly Report Q1 2024",
          "url": "https://ir.crinetics.com/quarterly-report-q1-2024",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![Crinetics Pharmaceuticals CRNX San Diego Logo](/sites/g/files/knoqqb69441/themes/site/nir_pid2888/client/images/Crinetics_Logo_onWhite.png) ](https://www.crinetics.com/)\n\n  * [Pipeline](https://crinetics.com/pipeline/)\n    * [Research Pipeline](https://crinetics.com/pipeline/)\n    * [Paltusotine](https://crinetics.com/pipeline/paltusotine-oral-sst2-selective-agonist-acromegaly-neuroendocrine-tumors-nets/)\n    * [CRN04894, Oral ACTH Antagonist](https://crinetics.com/pipeline/crn04894-cushings-disease-cah/)\n    * [Oral PTH Antagonist](https://crinetics.com/oral-pth-antagonist-treatment-of-hypercalcemia/)\n  * [Patients](https://crinetics.com/patients/)\n    * [Clinical Trials](https://crinetics.com/what-are-clinical-trials-why-are-they-important/)\n    * [Expanded Access Policy](https://crinetics.com/expanded-access-policy/)\n    * [Letter to Acromegaly Community](https://crinetics.com/acromegaly-community-pathfndr1-letter/)\n    * [Patient Videos >](https://crinetics.com/)\n      * [Clinical Trials](https://crinetics.com/patient-video-acromegaly-clinical-trials/)\n      * [Acromegaly in a Pandemic](https://crinetics.com/acromegaly-covid19-pandemic/)\n      * [Acromegaly Symptoms](https://crinetics.com/patient-video-acromegaly-symptoms/)\n      * [Acromegaly Diagnosis](https://crinetics.com/patient-video-acromegaly-diagnosis/)\n      * [Acromegaly Advocate](https://crinetics.com/patient-video-acromegaly-be-your-own-advocate/)\n      * [Acromegaly Support](https://crinetics.com/patient-video-acromegaly-finding-support/)\n  * [Professionals](https://crinetics.com/professionals/)\n    * [Acromegaly](https://crinetics.com/acromegaly-symptoms-diagnosis-treatment-resources/)\n    * [Carcinoid Syndrome](https://crinetics.com/carcinoid-syndrome-symptoms-diagnosis-treatment/)\n  * [Investors](/)\n    * [Overview](https://ir.crinetics.com/)\n    * [Corporate Presentation](/investor-resources/corporate-presentation)\n    * [SEC Filings](/investor-resources/sec-filings)\n    * [Stock Information](/investor-resources/stock-information)\n    * [Corporate Governance](/investor-resources/corporate-governance)\n    * [Press Releases](https://crinetics.com/press-releases/)\n    * [Events & Presentations](https://crinetics.com/events/)\n    * [Analyst Coverage](/investor-resources/analyst-coverage)\n    * [Investor Resources](/investor-resources)\n    * [Unmet Medical Need in Acromegaly](https://crinetics.com/access-current-treatment-landscape-and-unmet-medical-need-in-acromegaly-webinar/)\n  * [About Us](https://crinetics.com/about-crinetics-pharmaceuticals-crnx/)\n    * [Meet Us](https://crinetics.com/about-us/)\n    * [Employee Spotlight](https://crinetics.com/careers/culture/employee-spotlight/)\n    * [Culture](https://crinetics.com/careers/culture/)\n    * [Community](https://www.crinetics.com/about/community/)\n  * [Careers](https://crinetics.com/careers/)\n    * [Culture >](https://crinetics.com/careers/culture/)\n    * [Job Listings](https://crinetics.com/careers/job-listings/)\n    * [Benefits](https://crinetics.com/careers/benefits/)\n  * [Contact](https://crinetics.com/contact/)\n    * [Contact Us](https://crinetics.com/contact/)\n    * [Partnering](https://crinetics.com/partnering/)\n    * [Grants and Funding](https://crinetics.com/contact/grants-and-funding/)\n\n\n\n<https://www.crinetics.com/wp-content/uploads/2020/07/808-Rotation-D3.mp4>\n\n#  Page Not Found \n\n### [Events ![Events link](/system/files-encrypted/nasdaq_kms/inline-images/Crin_Home_Boxes_Grey-432x240-Events.jpg) ](https://crinetics.com/events/)\n\n### [Press Releases ![Press Releases link](/system/files-encrypted/nasdaq_kms/inline-images/Crin_Home_Box_PressRelease_Grey-uai-720x400.jpg) ](https://crinetics.com/press-releases/)\n\n### [Investor Home ![Investor Home](/system/files-encrypted/nasdaq_kms/inline-images/Crin_Home_Box_Financials_Grey-uai-720x400.jpg) ](/)\n\n##  Investor Resources\n\n  * [Corporate Presentation>](/investor-resources/corporate-presentation)\n  * [Stock Information>](/investor-resources/stock-information)\n  * [SEC Filings>](/investor-resources/sec-filings)\n  * [Analyst Coverage>](/investor-resources/analyst-coverage)\n  * [Investor FAQ>](/investor-resources/investor-faq)\n  * [Corporate Governance>](/investor-resources/corporate-governance)\n  * [Committee>](/investor-resources/committee-composition)\n  * [IR Home>](/)\n\n\n\n# Page Not Found\n\nWe are sorry, the page you requested cannot be found. Please check the URL or visit our [Homepage](/).\n\n  * ### [Email Alerts ](/#email-alerts \"Email Alerts\")\n  * ### [RSS Feeds ](/investor-resources/rss-feeds \"RSS Feeds\")\n  * ### [Print ](javascript:window.print\\(\\); \"Print\")\n  * ### [Email Page ](# \"Email Page\")\n\n\n\n### [Events ![Events link](/system/files-encrypted/nasdaq_kms/inline-images/Crin_Home_Boxes_Grey-432x240-Events.jpg) ](https://crinetics.com/events/)\n\n### [Press Releases ![Press Releases link](/system/files-encrypted/nasdaq_kms/inline-images/Crin_Home_Box_PressRelease_Grey-uai-720x400.jpg) ](https://crinetics.com/press-releases/)\n\n### [Investor Home ![Investor Home](/system/files-encrypted/nasdaq_kms/inline-images/Crin_Home_Box_Financials_Grey-uai-720x400.jpg) ](/)\n\n## Contact\n\n  * [Press Releases & Events>](#email-alerts-two)\n  * [Financial Alerts>](#email-alerts-one)\n  * [Media Inquiries>](#media-inquiries)\n  * [Contact IR>](#contact-ir)\n\n\n\nRequired fields denoted by an asterisk ().\n\nHide lower priority columns\n\nAlert type  \n---  \nQuote  \nSEC Filing  \nWeekly Summary  \n  \nEmail\n\n*By clicking Submit, you agree to our [privacy policy](https://crinetics.com/privacy-policy.)\n\nLeave this field blank\n\nFirst Name\n\nLast Name\n\nemail@address.com\n\nOrganization\n\nMessage\n\nLeave this field blank\n\n##  Contact\n\n[ Press Releases & Events> ](#1600129535-2-99)\n\n[ Financial Alerts> ](#1600129535-2-42)\n\nRequired fields denoted by an asterisk ().\n\nHide lower priority columns\n\nAlert type  \n---  \nQuote  \nSEC Filing  \nWeekly Summary  \n  \nEmail\n\n*By clicking Submit, you agree to our [privacy policy](https://crinetics.com/privacy-policy.)\n\nLeave this field blank\n\n[ Media Inquiries> ](#1600129613243-24-8)\n\n[ Contact IR> ](#1600129613243-2-8)\n\nFirst Name\n\nLast Name\n\nemail@address.com\n\nOrganization\n\nMessage\n\nLeave this field blank\n\n[](#)\n\n### Privacy Preference Center\n\n#### Privacy Preferences\n"
        }
      ]
    }
  ]
}